| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/15563650.2016.1271126 |
| P698 | PubMed publication ID | 28084171 |
| P50 | author | Andrew H. Dawson | Q37379168 |
| Nicholas A. Buckley | Q37386383 | ||
| Betty Chan | Q89754310 | ||
| P2860 | cites work | Almost a tragedy: severe methotrexate toxicity in a hemodialysis patient treated for ectopic pregnancy | Q33411737 |
| Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients | Q33417409 | ||
| Acute methotrexate ingestions in adults: a report of serious clinical effects and treatments | Q33562915 | ||
| A tribute to Sidney Farber-- the father of modern chemotherapy | Q33997155 | ||
| Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome. | Q34131794 | ||
| Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients | Q34247793 | ||
| Methotrexate for ectopic pregnancy: when and how. | Q34418588 | ||
| Evaluating performance of a decision support system to improve methotrexate pharmacotherapy in children and young adults with cancer | Q34780653 | ||
| Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases | Q35049306 | ||
| High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients | Q35640471 | ||
| Position Paper on urine alkalinization | Q35745550 | ||
| Defining the appropriate dosage of folinic acid after high-dose methotrexate for childhood acute lymphatic leukemia that will prevent neurotoxicity without rescuing malignant cells in the central nervous system | Q35763862 | ||
| Understanding and managing methotrexate nephrotoxicity | Q36516151 | ||
| Four-year experience with methotrexate exposures | Q36548419 | ||
| The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue. | Q37081539 | ||
| Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232 | Q37169331 | ||
| Fatal pancytopenia in a hemodialysis patient after treatment with low-dose methotrexate. | Q37510473 | ||
| Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy | Q37708963 | ||
| Successful use of intrathecal carboxypeptidase G2 for intrathecal methotrexate overdose: a case study and review of the literature | Q38053652 | ||
| How long can folinic acid rescue be delayed after high-dose methotrexate without toxicity? | Q38137967 | ||
| Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function | Q38208131 | ||
| The past versus the present, 1980-2004: reduction of mean initial low-dose, long-term glucocorticoid therapy in rheumatoid arthritis from 10.3 to 3.6 mg/day, concomitant with early methotrexate, with long-term effectiveness and safety of less than 5 | Q38250274 | ||
| A decade of Australian methotrexate dosing errors | Q38852300 | ||
| Methotrexate: clinical pharmacology, current status and therapeutic guidelines | Q39660818 | ||
| The clinical pharmacology of methotrexate.new applications of an old drug | Q39716312 | ||
| Clinical Pharmacokinetics of Methotrexate1 | Q39720628 | ||
| Pharmacokinetics of high-dose methotrexate in infants aged less than 12 months treated for aggressive brain tumors. | Q39911676 | ||
| The clinical pharmacology of methotrexate | Q40149030 | ||
| Increased therapeutic index using moderate dose methotrexate and leucovorin twice weekly vs. weekly high dose methotrexate-leucovorin in patients with advanced squamous carcinoma of the head and neck: a safe new effective regimen | Q42261781 | ||
| Methotrexate and citrovorum factor rescue in the management of childhood lymphosarcoma and reticulum cell sarcoma (non-Hodgkin's lymphomas): parolonged unmaintained remissions | Q44456216 | ||
| Pancytopenia related to low-dose methotrexate: study of five cases and review of the literature | Q44498528 | ||
| High dose methotrexate therapy of solid tumors: observations relating to clinical toxicity | Q44502873 | ||
| Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease | Q44505159 | ||
| Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis | Q45081072 | ||
| Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2. | Q45115245 | ||
| Statistical analysis of relation between plasma methotrexate concentration and toxicity in high-dose methotrexate therapy of childhood nonHodgkin lymphoma | Q45147872 | ||
| High dose methotrexate in adult patients with osteosarcoma: clinical and pharmacokinetic results. | Q46667668 | ||
| Retrospective study on elimination delay of methotrexate in high-dose therapy of childhood acute lymphoblastic leukemia in China | Q46961911 | ||
| Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. | Q50695569 | ||
| Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies. | Q53085288 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | poisoning | Q114953 |
| methotrexate | Q422232 | ||
| P304 | page(s) | 88-96 | |
| P577 | publication date | 2017-02-01 | |
| P1433 | published in | Clinical Toxicology | Q1101545 |
| P1476 | title | What can clinicians learn from therapeutic studies about the treatment of acute oral methotrexate poisoning? | |
| P478 | volume | 55 |
| Q47102539 | Accidental Chronic Poisoning with Methotrexate; Report of Two Cases |
| Q91590678 | Acute versus chronic methotrexate poisoning; a cross-sectional study |
| Q38668482 | Evaluation of toxicity after acute accidental methotrexate ingestions in children under 6 years old: a 16-year multi-center review. |
| Q48232372 | Is it really safe to withhold folinic acid when less than 1000 mg/m2 methotrexate is ingested? |
| Q53329376 | Response to the letter regarding "Is it really safe to withhold folinic acid when less than 1000 mg/m2 methotrexate is ingested?" |
Search more.